ClinicalTrials.gg

Program

selonabant

Also written as “ANEB-001” and “V24343”.

Its studies are mostly in Obesity, led by 2 companies.

Furthest: phase 2, since Mar 8, 20223 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Anebulo Pharmaceuticals20 open or runningphase 2since Mar 8, 2022Mar 8, 2022none ahead
Vernalis (R&D)10 open or runningphase 1since Aug 6, 2008Aug 6, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2008First study: phase 1 study in ObesityNew to Vernalis (R&D)Vernalis (R&D) · NCT00734201 · 32 enrolled · United Kingdom
  2. Mar 8, 2022Anebulo Pharmaceuticals's first study: phase 2 study in Acute Cannabinoid IntoxicationNew to Anebulo PharmaceuticalsAnebulo Pharmaceuticals · NCT05282797 · 154 enrolled · Netherlands
  3. Sep 29, 2025Phase 1 study in Healthy VolunteersAnebulo Pharmaceuticals · NCT07211607 · 40 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07211607Healthy Volunteers · United States1CompletedAnebulo PharmaceuticalsMay 6, 202640
NCT05282797Acute Cannabinoid Intoxication · Netherlands2CompletedAnebulo PharmaceuticalsAug 26, 2023154
NCT00734201Obesity · United Kingdom1CompletedVernalis (R&D)Mar 200932

How it is read

Names in the registry

  • “selonabant”, 1 entry
  • “ANEB-001”, 1 entry
  • “V24343”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.